The Noramco Group Invests $25 Million in Halo Pharma’s Whippany Facility to Offer Sterile Injectable Manufacturing
Press Release The Noramco Group, an integrated North American-based API and drug product supply chain product and services provider, today announced a $25 million investment in its Halo Pharma ...
MyChesCo on MSN7d
Noramco Group Invests $25 Million to Expand Sterile Injectable Manufacturing
The Noramco Group has announced a $25 million investment to expand its Halo Pharma facility in Whippany, New Jersey, by ...
Medscape3y
Oral Syringes: A Crucial and Economical Risk-reduction Strategy that has Not been Fully Utilized
After filling a parenteral syringe with an oral/enteral medication, it takes a momentary mental lapse to connect it to an intravenous line and inject it. [1] To prevent this, oral syringes have ...
Contract Pharma13d
The Noramco Group Invests $25M into Halo Pharma Facility in NJ
The Noramco Group is investing $25M into its Halo Pharma facility in Whippany, NJ to establish sterile injectable ...
Business Wire13d
The Noramco Group Invests $25 Million in Halo Pharma’s Whippany Facility to Offer Sterile Injectable Manufacturing
The investment includes the installation of a high-speed, state-of-the-art Groninger UFVN FlexFill syringe, cartridge, and vial filling line and a SKAN isolator to enhance production efficiency ...